All Patients

ACPA+ and/or RF+ Patients

Abatacept n=100

TNFi n=165

P-Value

Abatacept n=55

TNFi n=108

P-Value

TNFi, n (%)

n/a

Adalimumab

-

67 (40.6)

-

44 (40.7)

Etanercept

-

55 (33.3)

-

36 (33.3)

Infliximab

-

28 (17.0)

-

20 (18.5)

Golimumab

-

11 (6.7)

-

6 (5.6)

Certolizumab Pegol

-

4 (2.4)

-

2 (1.9)

Clinic, n (%)

<0.001

0.002

1

5 (5.0)

33 (20.0)

5 (9.1)

27 (25.0)

2

24 (24.0)

42 (25.5)

16 (29.1)

30 (27.8)

3

45 (45.0)

22 (13.3)

16 (29.1)

12 (11.1)

4

10 (10.0)

51 (30.9)

6 (10.9)

27 (25.0)

5

5 (5.0)

11 (6.7)

4 (7.3)

6 (5.6)

6

11 (11.0)

6 (3.6)

8 (14.6)

6 (5.6)

Female, n (%)

82 (82.0)

121 (73.3)

0.106

46 (83.6)

78 (72.2)

0.106

Age in Years (in 2017), Mean (SD)

67.0 (13.6)

60.3 (12.2)

<0.001

64.5 (12.7)

59.4 (12.5)

0.014

CCI, Mean (SD)

0.7 (1.0)

0.5 (0.9)

0.080

0.7 (1.1)

0.5 (0.9)

0.170

Total Duration of Treatment at Clinic (years), Mean (SD)

5.7 (4.2)

5.2 (3.4)

0.288

5.1 (3.7)

4.8 (3.0)

0.575

No. Physician Office Visits (1-year pre-index), Mean (SD)

3.8 (2.4)

4.0 (3.4)

0.588

3.7 (2.2)

3.6 (2.3)

0.760

No. Hospitalizations (1-year pre-index), Mean (SD)

0.1 (0.4)^a

0.1 (0.3)^a

0.037

0.2 (0.4)^b

0.1 (0.4)^b

0.084